CVN424 is a potent and selective GPR6 inverse agonist (EC50 of 38 nM) for the treatment of parkinson's disease.

Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance.

WL47 is a selective, high-affinity, disrupter of cavolin-1 oligomers (Kd=23 nM) than BSA, casein, and HEWL. WL47 is a caveolin-1 (CAV1) ligand and is 80% smaller in length than the original T20 parent sequence. WL47 can be used for the study of caveolin-1 function.

WL47 TFA is a selective, high-affinity, disrupter of cavolin-1 oligomers (Kd=23 nM) than BSA, casein, and HEWL. WL47 TFA is a caveolin-1 (CAV1) ligand and is 80% smaller in length than the original T20 parent sequence. WL47 TFA can be used for the study of caveolin-1 function.

Idalopirdine, also known as Lu AE58054 or Iladopirdine, is a potent and selective 5-HT6 receptor antagonist under development by Lundbeck as an augmentation therapy for the treatment of cognitive deficits associated with Alzheimer's disease and schizophrenia. It is in phase III clinical trials. Lu AE58054 displayed high affinity to the human 5-HT(6) receptor (5-HT(6)R) with a Ki of 0.83 nm. Lu AE58054 demonstrated >50-fold selectivity for more than 70 targets examined. Lu AE58054 is a selective antagonist of 5-HT(6)Rs with good oral bioavailability and robust efficacy in a rat model of cognitive impairment in schizophrenia. Lu AE58054 may be useful for the pharmacotherapy of cognitive dysfunction in disease states such as schizophrenia and Alzheimer's disease.

Lu AE58054 is an in-vitro potency and selectivity, in-vivo binding affinity and effect of the 5-HT(6)R antagonist with a Ki value of 0.83 nM.

Bremelanotide acetate is an analogue of the naturally occurring peptide alpha-MSH.

JC-229 is a TbRPA1 inhibitor. JC-229 targets RPA1 in Trypanosoma brucei, the causative parasite of African trypanosomiasis. JC-229 is highly toxic to T. brucei cells, while mildly toxic to human cells. JC-229 treatment mimics the effects of TbRPA1 depletion, including DNA replication inhibition and DNA damage accumulation. JC-229 inhibits the activity of TbRPA1, but not the human ortholog.

AJ2-71 is a SLCl5A4 inhibitor.

AJ2-30 is a SLCl5A4 inhibitor.

LZWL02003 is a neuroprotective agent and derivative of N-salicyloyl tryptamine. LZWL02003 upregulated the expression of Bcl-2 and downregulated the expression of Bax, thus maintaining the homeostasis of Bcl-2/Bax proteins and preventing apoptosis. LZWL02003 also reduced oxidative stress by reducing malondialdehyde and reactive oxygen species levels, increasing the superoxide dismutase activity, and resolving mitochondrial malfunction. LZWL02003 can lower interleukin (IL)-1β, tumor necrosis factor (TNF)-α, and IL-6 levels, which in turn suppress neuroinflammation. LZWL02003 suppressed the phosphorylation activation of NF-κB pathway-related proteins and decreased the nuclear translocation of NF-κB p65 subunits. LZWL02003 is a neuroprotective agent with pleiotropic effects and may be a candidate for treating cerebral I/R injury.

Lenalidomide-acetylene-Br is a PROTAC Linker that makes up HJM-561.

WAY-299562 is a modulator of the interaction of protein kinase A (PKA) and A kinase anchor proteins (AKAP).

WAY-270250 is a IGF-1R/SRC inhibitor.

WAY-646458 is a Casein kinase 1d inhibitor.

WAY-625135 is a Casein kinase 1δ inhibitor.

WAY-311474 altering the lifespan of eukaryotic organisms.

WAY-304800-A is a Casein kinase 1δ inhibitor.

WAY-299359 is a FLT3 inhibitor

Anticancer agent 129 (Compound 3a), a quinoline derivative, predicting to has anti-cancer activity.

AChE-IN-30 is an AChE inhibitor.

Pim-1 kinase inhibitor 4 (Compound 10f) is a Pim-1 kinase inhibitor.

Danazol is a derivative of the synthetic steroid ethisterone that suppresses the production of gonadotropins and has some weak androgenic effects. Before becoming available as a generic drug, danazol was marketed as Danocrine in the United States. It was approved by the US Food and Drug Administration (FDA) as the first drug to specifically treat endometriosis in the early 1970s. Although effective for endometriosis, its use is limited by its masculinizing side-effects. Its role as a treatment for endometriosis has been largely replaced by the GnRH agonists.

PLX5622 is a a potent, selective, orally active inhibitor of CSF1R tyrosine kinase (c-Fms) activity with Ki of 5.9 nM, 60-fold less potency against KIT.

Calcifediol is a major circulating metabolite of vitamin D3, acting as a competitive inhibitor with an apparent Ki of 3.9 μM, suppresses PTH secretion and mRNA (ED50=2 nM).

ZT-1a is a potent, non-ATP-competitive and selective SPAK inhibitor. ZT-1a inhibits SPAK activity with IC50s of 44.3, 35.0, 46.7 μM at ATP concentrations of 0.01, 0.1 and 1 mM, respectively.

Ailanthone (Δ13-Dehydrochaparrinone) is a potent inhibitor of both full-length androgen receptor (AR) (IC50=69 nM) and constitutively active truncated AR splice variants (AR1-651 IC50=309 nM).

Cell permeable cAMP analog, acting as a cardiac stimulant and inhibiting phosphodiesterase

c-FMS-IN-8 is a potent, selective c-FMS kinase inhibitor with IC50 of 0.8 nM, shows activity in collagen-induced model of arthritis in mice..

D,L-Buthionine-(S,R)-sulfoximine is a potent inhibitor of glutamylcysteine synthetase biosynthesis.